In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:<ul><li>MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM </li><li>RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary disease</li><li>CARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogenetics</li><li>STEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapy</li><li>CAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MM</li></ul>Presenter:Shaji K. Kumar, MD Mark and Judy Mullins Professor of Hematological Malignancies Consultant, Division of Hematology Professor of Medicine Research Chair, Division of Hematology Mayo Clinic Rochester, MinnesotaLink to full program:  <a href="https://bit.ly/4995nFA" target="_blank">https://bit.ly/4995nFA</a> Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.

<description>&lt;p&gt;In this episode, Shaji K. Kumar, MD, reviews key highlights from ASH 2025 in multiple myeloma (MM), focusing on emerging data for bispecific antibodies and CAR T-cell therapies across earlier and later lines of treatment. The discussion covers the following:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;MajesTEC-3: Results from the phase III study of teclistamab + daratumumab in R/R MM &lt;/li&gt;&lt;li&gt;RedirecTT-1: Updated efficacy and safety of talquetamab + teclistamab in R/R MM and extramedullary disease&lt;/li&gt;&lt;li&gt;CARTITUDE-4: Results following treatment with cilta-cel in patients with standard-risk cytogenetics&lt;/li&gt;&lt;li&gt;STEM: Preliminary safety and efficacy data from the phase II study of cevostamab consolidation following BCMA-directed CAR T-cell therapy&lt;/li&gt;&lt;li&gt;CAMMA1: Biomarker analyses from Arm B following cevostamab + pomalidomide and dexamethasone treatment in patients with R/R MM&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;strong&gt;Presenter:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Shaji K. Kumar, MD&lt;/strong&gt;&lt;br /&gt;Mark and Judy Mullins Professor of Hematological Malignancies&lt;br /&gt;Consultant, Division of Hematology&lt;br /&gt;Professor of Medicine&lt;br /&gt;Research Chair, Division of Hematology&lt;br /&gt;Mayo Clinic&lt;br /&gt;Rochester, Minnesota&lt;/p&gt;&lt;p&gt;Link to full program: &lt;br /&gt;&lt;a href="https://bit.ly/4995nFA" target="_blank"&gt;https://bit.ly/4995nFA&lt;/a&gt;&lt;/p&gt;&lt;br/&gt; &lt;p&gt;Hosted by Simplecast, an AdsWizz company. See &lt;a href="https://pcm.adswizz.com"&gt;pcm.adswizz.com&lt;/a&gt; for information about our collection and use of personal data for advertising.&lt;/p&gt;</description>

This episode features Dr Shaji K. Kumar reviewing pivotal data on the efficacy, safety, and expanding roles of immunotherapy approaches in multiple myeloma, including bispecific antibodies, CAR T-cell therapies, and novel combination strategies. 

PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting

In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:<ul><li>CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL </li><li>BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLL</li><li>BRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL </li><li>EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FL</li><li>STARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCL</li></ul>Presenter: Jeremy S. Abramson, MD, MMSc Professor of Medicine Harvard Medical School Director, Center for Lymphoma Mass General Brigham Cancer Ins Boston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program: <a href="https://bit.ly/4aqMobZ" target="_blank">https://bit.ly/4aqMobZ</a> Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.

<description>&lt;p&gt;In this podcast episode, Jeremy S. Abramson, MD, MMSc, reviews data from select presentations in lymphomas at the ASH 2025 Annual Meeting and provides perspectives on the clinical implications of these data for patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL), including:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;CLL17: randomized phase III trial of continuous ibrutinib vs fixed-duration venetoclax plus obinutuzumab or venetoclax plus ibrutinib for untreatedCLL &lt;/li&gt;&lt;li&gt;BRUIN CLL-313: randomized phase III trial of pirtobrutinib vs BR for previously untreated patients with CLL&lt;/li&gt;&lt;li&gt;BRUIN CLL-314: pirtobrutinib vs ibrutinib in treatment-naive and BTKi-naive R/R CLL/SLL &lt;/li&gt;&lt;li&gt;EPCORE-FL-1: randomized phase III trial of epcoritamab with rituximab and lenalidomide vs rituximab and lenalidomide for R/R FL&lt;/li&gt;&lt;li&gt;STARGLO: 3-year follow-up data from the randomized phase III trial of glofitamab plus GemOx vs rituximab plus GemOx for patients with R/R DLBCL&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;strong&gt;Presenter&lt;/strong&gt;: &lt;/p&gt;&lt;p&gt;&lt;strong&gt;Jeremy S. Abramson, MD, MMSc&lt;/strong&gt;&lt;br /&gt;Professor of Medicine&lt;br /&gt;Harvard Medical School&lt;br /&gt;Director, Center for Lymphoma&lt;br /&gt;Mass General Brigham Cancer Ins&lt;br /&gt;Boston, Massachusetts&lt;/p&gt;&lt;p&gt;Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson &amp; Johnson, Lilly, and Novartis Pharmaceuticals Corporation.&lt;/p&gt;&lt;p&gt;Link to full program:&lt;br /&gt;&lt;a href="https://bit.ly/4aqMobZ" target="_blank"&gt;https://bit.ly/4aqMobZ&lt;/a&gt;&lt;/p&gt;&lt;br/&gt; &lt;p&gt;Hosted by Simplecast, an AdsWizz company. See &lt;a href="https://pcm.adswizz.com"&gt;pcm.adswizz.com&lt;/a&gt; for information about our collection and use of personal data for advertising.&lt;/p&gt;</description>

Listen to Jeremy S. Abramson, MD, MMSc, discuss key findings from select studies in lymphomas presented at the ASH 2025 Annual Meeting, including perspectives on the clinical implications of the data for patients with CLL, FL, and DLBCL.

PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting

In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: <ul><li>LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment</li><li>Abstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapy</li><li>Abstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infections</li><li>Abstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand disease</li><li>Abstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitors</li></ul>Presenter: Hanny Al-Samkari, MD The Peggy S. Blitz Endowed Chair in Hematology/Oncology Co-Director, Hereditary Hemorrhagic Telangiectasia Center of Excellence Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program: <a href="https://bit.ly/48Ye45N" target="_blank">https://bit.ly/48Ye45N</a> Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.

<description>&lt;p&gt;In this episode, Hanny Al-Samkari, MD, gives his thoughts on 5 key presentations from ASH 2025, and provides perspectives on the clinical implications of these data for patients with nonmalignant hematologic disorders such as ITP and vWD, including: &lt;/p&gt;&lt;ul&gt;&lt;li&gt;LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase III trial of ianalumab plus eltrombopag vs placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment&lt;/li&gt;&lt;li&gt;Abstract 844: Secondary analysis results from VAYHIT3, a phase II study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least 2 lines of therapy&lt;/li&gt;&lt;li&gt;Abstract 5: Deciphering the dilemma: intravenous (IV) iron use in iron deficiency anemia during acute infections&lt;/li&gt;&lt;li&gt;Abstract 308: Subcutaneous, every-4-week maintenance dosing of a novel protein S antibody is well tolerated and substantially reduces bleeding rates: results from a phase I/II multidose study of VGA039 in patients with von Willebrand disease&lt;/li&gt;&lt;li&gt;Abstract 841: Immune thrombocytopenia in patients treated with immune checkpoint inhibitors&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Presenter:&lt;br /&gt;&lt;strong&gt;Hanny Al-Samkari, MD&lt;/strong&gt;&lt;br /&gt;The Peggy S. Blitz Endowed Chair in Hematology/Oncology&lt;br /&gt;Co-Director, Hereditary Hemorrhagic Telangiectasia Center of Excellence&lt;br /&gt;Massachusetts General Hospital&lt;br /&gt;Associate Professor of Medicine&lt;br /&gt;Harvard Medical School&lt;br /&gt;Boston, Massachusetts&lt;/p&gt;&lt;p&gt;Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson &amp; Johnson, Lilly, and Novartis Pharmaceuticals Corporation.&lt;/p&gt;&lt;p&gt;Link to full program:&lt;br /&gt;&lt;a href="https://bit.ly/48Ye45N" target="_blank"&gt;https://bit.ly/48Ye45N&lt;/a&gt;&lt;/p&gt;&lt;br/&gt; &lt;p&gt;Hosted by Simplecast, an AdsWizz company. See &lt;a href="https://pcm.adswizz.com"&gt;pcm.adswizz.com&lt;/a&gt; for information about our collection and use of personal data for advertising.&lt;/p&gt;</description>

Listen to Hanny Al-Samkari, MD, discuss key findings from select studies in nonmalignant hematologic disorders presented at the 2025 ASH Annual Meeting, including perspectives on the clinical implications of the data for patients with ITP and vWD.

PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting

In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:<ul><li>Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AML</li><li>Abstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AML</li><li>Abstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed NPM1-mutant AML</li><li>Abstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapy</li><li>Abstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CML</li><li>Abstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKI</li></ul>Presenter: Amir T. Fathi, MD Director, Leukemia Program Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Boston, MassachusettsContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program: <a href="https://bit.ly/48Ye45N" target="_blank">https://bit.ly/48Ye45N</a> Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.

<description>&lt;p&gt;In this podcast episode, Amir T. Fathi, MD, reviews data from select presentations in leukemias at the ASH 2025 Annual Meeting, and provides perspectives on the clinical implications of these data for patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML), including:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;Abstract 6: Phase II PARADIGM trial of azacitidine and venetoclax vs conventional intensive chemotherapy for fit patients with newly diagnosed AML&lt;/li&gt;&lt;li&gt;Abstract 47: Phase I/II SAVE trial of revumenib plus decitabine/cedazuridine and venetoclax in the cohort of patients with newly diagnosed AML&lt;/li&gt;&lt;li&gt;Abstract 766: Phase Ib KOMET-007 trial of ziftomenib in combination with venetoclax and azacitidine in newly diagnosed &lt;i&gt;NPM1&lt;/i&gt;-mutant AML&lt;/li&gt;&lt;li&gt;Abstract 654: Phase I/II VICEROY trial of venetoclax and azacitidine + gilteritinib in patients with newly diagnosed &lt;i&gt;FLT3&lt;/i&gt;-mutated AML ineligible for intensive induction chemotherapy&lt;/li&gt;&lt;li&gt;Abstract 903: 3-Yr Update of the phase II FASCINATION trial of asciminib and conventional BCR::ABL1 inhibitors in newly diagnosed CML&lt;/li&gt;&lt;li&gt;Abstract 906: Phase II ASC2ESCALATE trial of asciminib in patients with chronic-phase CML after 1 prior TKI&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;Presenter:&lt;br /&gt;&lt;strong&gt;Amir T. Fathi, MD&lt;/strong&gt;&lt;br /&gt;Director, Leukemia Program&lt;br /&gt;Massachusetts General Hospital&lt;br /&gt;Associate Professor of Medicine&lt;br /&gt;Harvard Medical School&lt;br /&gt;Boston, Massachusetts&lt;/p&gt;&lt;p&gt;Content based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson &amp; Johnson, Lilly, and Novartis Pharmaceuticals Corporation.&lt;/p&gt;&lt;p&gt;Link to full program:&lt;br /&gt;&lt;a href="https://bit.ly/48Ye45N" target="_blank"&gt;https://bit.ly/48Ye45N&lt;/a&gt;&lt;/p&gt;&lt;br/&gt; &lt;p&gt;Hosted by Simplecast, an AdsWizz company. See &lt;a href="https://pcm.adswizz.com"&gt;pcm.adswizz.com&lt;/a&gt; for information about our collection and use of personal data for advertising.&lt;/p&gt;</description>

Listen to Amir T. Fathi, MD, discuss key findings from select studies in leukemias presented at the ASH 2025 Annual Meeting, including perspectives on the clinical implications of the data for patients with AML or CML.

PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:<ul><li>TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan </li><li>TROP2 ADCS for patients with EGFR-mutated NSCLC</li><li>TIGIT-targeting agents: domvanalimab, rilvegostomig</li></ul>Presenters:Benjamin Levy, MD, FASCO Associate Professor Johns Hopkins School of Medicine Clinical Director Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR) Washington, DCAlex Spira, MD, PhD, FASCO Director Clinical Research Virginia Cancer Specialists CEO NEXT Oncology Virginia Fairfax, VirginiaContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: <a href="https://bit.ly/4qZLR6B" target="_blank">https://bit.ly/4qZLR6B</a> Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.

<description>&lt;p&gt;In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including:&lt;/p&gt;&lt;ul&gt;&lt;li&gt;TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan &lt;/li&gt;&lt;li&gt;TROP2 ADCS for patients with &lt;i&gt;EGFR&lt;/i&gt;-mutated NSCLC&lt;/li&gt;&lt;li&gt;TIGIT-targeting agents: domvanalimab, rilvegostomig&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&lt;strong&gt;Presenters:&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;Benjamin Levy, MD, FASCO&lt;br /&gt;Associate Professor&lt;br /&gt;Johns Hopkins School of Medicine&lt;br /&gt;Clinical Director&lt;br /&gt;Johns Hopkins Kimmel Cancer Center, National Capitol Region (NCR)&lt;br /&gt;Washington, DC&lt;/p&gt;&lt;p&gt;Alex Spira, MD, PhD, FASCO&lt;br /&gt;Director Clinical Research&lt;br /&gt;Virginia Cancer Specialists&lt;br /&gt;CEO NEXT Oncology Virginia&lt;br /&gt;Fairfax, Virginia&lt;/p&gt;&lt;p&gt;Content based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.&lt;/p&gt;&lt;p&gt;Link to full program:&lt;br /&gt;&lt;a href="https://bit.ly/4qZLR6B" target="_blank"&gt;https://bit.ly/4qZLR6B&lt;/a&gt;&lt;/p&gt;&lt;br/&gt; &lt;p&gt;Hosted by Simplecast, an AdsWizz company. See &lt;a href="https://pcm.adswizz.com"&gt;pcm.adswizz.com&lt;/a&gt; for information about our collection and use of personal data for advertising.&lt;/p&gt;</description>

Listen to experts Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer.

TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today?

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Decera Clinical Education Oncology Podcast

Details

Recent Episodes